Trial Profile
A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 to 75 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (QuANTUM First)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Quizartinib (Primary) ; Cytarabine; Daunorubicin; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms QuANTUM-First
- Sponsors Daiichi Sankyo Inc
- 12 Dec 2023 Results of Patient-Reported Outcomes , presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results assessing the impact of CR duration on OS and EFS and the kinetics of CR achievement over time after induction , presented at the 65th American Society of Hematology Annual Meeting and Exposition